Kan man medicinera med cbd vid lungfibros

1. Agarwal, A. K., & Huda, N. (2023). Interstitial Pulmonary Fibrosis. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK557765/

2. Ali, A. M., El-Tawil, O. S., Al-Mokaddem, A. K., & Abd El-Rahman, S. S. (2021). Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling bygd cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced bygd thioacetamide. Chemico-Biological Interactions, 336, 109398. https://doi.org/10.1016/j.cbi.2021.109398

3. Association, A. L. (n.d.-a). Marijuana and Lung Health. Retrieved May 3, 2023, from https://www.lung.org/quit-smoking/smoking-facts/health-effects/marijuana-and-lung-health

4. Association, A. L. (n.d.-b). Types, Causes and fara Factors of Pulmonary Fibrosis. Retrieved April 17, 2023, from https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-fibrosis/introduction/types-causes-and-risk-factors

5. Barratt, S. L., Creamer, A., Hayton, C., & Chaudhuri, N. (2018). Idiopathic Pulmonary Fibrosis (IPF): An Overview. Journal of Clinical Medicine, 7(8), 201. https://doi.org/10.3390/jcm7080201

6. Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019). Fibrosing interstitial lung diseases: Knowns and unknowns. European Respiratory Review, 28(151). https://doi.org/10.1183/16000617.0100-2018

7. Could Cannabis Help People With Lung Diseases? | Pulmonary Fibrosis News. (n.d.). Retrieved April 17, 2023, from https://pulmonaryfibrosisnews.com/pulmonary-fibrosis-social-clips/cannabis-help-people-lung-diseases/

8. Fu, Q., Zheng, Y., Dong, X., Wang, L., & Jiang, C. G. (2017). Activation of cannabinoid receptor type 2 bygd JWH133 alleviates bleomycin-induced pulmonary fibrosis in mice. Oncotarget, 8(61), 103486–103498. https://doi.org/10.18632/oncotarget.21975

9. Garcia-Gonzalez, E., Selvi, E., Balistreri, E., Lorenzini, S., Maggio, R., Natale, M.-R., Capecchi, P.-L., Lazzerini, P.-E., Bardelli, M., Laghi-Pasini, F., & Galeazzi, M. (2009). Cannabinoids hämma fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford, England), 48(9), 1050–1056. https://doi.org/10.1093/rheumatology/kep189

10. Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis Foundation. (n.d.). Default. Retrieved April 17, 2023, from https://www.pulmonaryfibrosis.org/understanding-pff/types-of-pulmonary-fibrosis/idiopathic-pulmonary-fibrosis

11. Idiopathic Pulmonary Fibrosis – What fryst vatten Idiopathic Pulmonary Fibrosis? | NHLBI, NIH. (2022, March 24). https://www.nhlbi.nih.gov/health/idiopathic-pulmonary-fibrosis

12. Idiopathic pulmonary fibrosis, the endocannabinoid struktur and cannabinoids | Fundación CANNA: Scientific studies and cannabis testing. (n.d.). Retrieved April 17, 2023, from https://www.fundacion-canna.es/en/idiopathic-pulmonary-fibrosis-endocannabinoid-system-and-cannabinoids

13. Interstitial Lung Disease and Pulmonary Fibrosis | Columbia Surgery. (n.d.). Retrieved April 17, 2023, from https://columbiasurgery.org/conditions-and-treatments/interstitial-lung-disease-and-pulmonary-fibrosis

14. Interstitial Lung Disease: Pulmonary Fibrosis. (2021, August 8). https://www.hopkinsmedicine.org/health/conditions-and-diseases/interstitial-lung-disease-pulmonary-fibrosis

15. Interstitial lung disease—Symptoms and causes. (n.d.). Mayo vårdcentral. Retrieved April 17, 2023, from https://www.mayoclinic.org/diseases-conditions/interstitial-lung-disease/symptoms-causes/syc-20353108

16. Kalchiem-Dekel, O., Galvin, J. R., Burke, A. P., Atamas, S. P., & Todd, N. W. (2018). Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General medicin Physicians with Focus on the Medical History. Journal of Clinical Medicine, 7(12), 476. https://doi.org/10.3390/jcm7120476

17. Kaplan, A. G. (2021). Cannabis and Lung Health: Does the Bad Outweigh the Good? Pulmonary Therapy, 7(2), 395–408. https://doi.org/10.1007/s41030-021-00171-8

18. Kendall, R. T., & Feghali-Bostwick, C. A. (2014). Fibroblasts in fibrosis: Novel roles and mediators. Frontiers in Pharmacology, 5, 123. https://doi.org/10.3389/fphar.2014.00123

19. Kicman, A., Pędzińska-Betiuk, A., & Kozłowska, H. (2021). The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases. European Journal of Pharmacology, 911, 174560.https://doi.org/10.1016/j.ejphar.2021.174560

20. Kovalchuk, O., & Kovalchuk, inom. (2020). Cannabinoids as anticancer therapeutic agents. Cell Cycle, 19(9), 961–989. https://doi.org/10.1080/15384101.2020.1742952

21. Krishna, R., Chapman, K., & Ullah, S. (2023). Idiopathic Pulmonary Fibrosis. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK448162/

22. Krzyżewska, A., Baranowska-Kuczko, M., Kasacka, I., & Kozłowska, H. (2022). Cannabidiol reduces lung and heart fibrosis in rats with monocrotaline-induced pulmonary hypertension. European Respiratory Journal, 60(suppl 66). https://doi.org/10.1183/13993003.congress-2022.4477

23. Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017). Drugs and Targets in Fibrosis. Frontiers in Pharmacology, 8, 855. https://doi.org/10.3389/fphar.2017.00855

24. Luke, N. D., Vefali, B., Chow, P., Miller, R., Luke, N. D., Vefali, B., Chow, P., & Miller, R. (2023). Acute Recreational Cannabis-Induced Hypersensitivity Pneumonitis: A Case Report. Cureus, 15(4). https://doi.org/10.7759/cureus.37312

25. Mallat, A., Teixeira-Clerc, F., Deveaux, V., Manin, S., & Lotersztajn, S. (2011). The endocannabinoid struktur as a key mediator during liver diseases: New insights and therapeutic openings. British Journal of Pharmacology, 163(7), 1432–1440. https://doi.org/10.1111/j.1476-5381.2011.01397.x

26. Martinez-Pitre, P., Sabbula, B., & Cascella, M. (2022). Restrictive Lung Disease. StatPearls. https://www.statpearls.com/ArticleLibrary/viewarticle/90190

27. McGrail, J., Martín-Banderas, L., & Durán-Lobato, M. (2022). Cannabinoids as framträdande Therapy Against COVID-19. Cannabis and Cannabinoid Research, 7(5), 582–590. https://doi.org/10.1089/can.2022.0018

28. Montecucco, F., & Di Marzo, V. (2012). At the heart of the matter: The endocannabinoid struktur in cardiovascular function and dysfunction. Trends in Pharmacological Sciences, 33(6), 331–340. https://doi.org/10.1016/j.tips.2012.03.002

29. Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1(7), 1333–1349. https://doi.org/10.4155/fmc.09.93

30. Phan, T., Lau, K., & Li, X. (2005). Lung bullae and pulmonary fibrosis associated with marijuana smoking. Australasian Radiology, 49, 411–414. https://doi.org/10.1111/j.1440-1673.2005.01472.x

31. Pinheiro, G. A., Antao, V. C., Wood, J. M., & Wassell, J. T. (2008). Occupational Risks for Idiopathic Pulmonary Fibrosis Mortality in the United States. International Journal of Occupational and Environmental Health, 14(2), 117–123. https://doi.org/10.1179/oeh.2008.14.2.117

32. Preteroti, M., efternamn, E. T., Eidelman, D. H., & Baglole, C. J. (2023). Modulation of pulmonary immune function bygd inhaled cannabis products and consequences for lung disease. Respiratory Research, 24(1), 95. https://doi.org/10.1186/s12931-023-02399-1

33. Pryimak, N., Zaiachuk, M., Kovalchuk, O., & Kovalchuk, inom. (2021). The Potential Use of Cannabis in Tissue Fibrosis. Frontiers in fängelse and Developmental Biology, 9, 715380. https://doi.org/10.3389/fcell.2021.715380

34. Pulmonary Fibrosis. (n.d.). [Text]. National Library of medicin. Retrieved April 17, 2023, from https://medlineplus.gov/pulmonaryfibrosis.html

35. Ribeiro, L. I., & Ind, P. W. (2016). Effect of cannabis smoking on lung function and respiratory symptoms: A structured literature review. Npj Primary Care Respiratory Medicine, 26(1), Article 1. https://doi.org/10.1038/npjpcrm.2016.71

36. Sido, J. M., Jackson, A. R., Nagarkatti, P. S., & Nagarkatti, M. (2016). Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. Journal of Molecular medicin (Berlin, Germany), 94(9), 1039–1051. https://doi.org/10.1007/s00109-016-1404-5

37. Turcotte, C., Blanchet, M.-R., Laviolette, M., & Flamand, N. (2016). The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences, 73(23), 4449–4470. https://doi.org/10.1007/s00018-016-2300-4

38. Understanding ILD. (n.d.). Interstitial Lung Disease schema. Retrieved April 17, 2023, from https://med.stanford.edu/ild/patient-resources/understanding-ild.html

39. Vuolo, F., Abreu, S., Michels, M., Xisto, D., Blanco, N., Hallak, J., Zuardi, A., Crippa, J., Reis, C., Bahl, M., Pizzichinni, E., Maurici, R., Pizzichinni, M., Rocco, P., & Dal-Pizzol, F. (2018). Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. European Journal of Pharmacology, 843. https://doi.org/10.1016/j.ejphar.2018.11.029

40. Wang, B., Kovalchuk, A., Li, D., Rodriguez-Juarez, R., Ilnytskyy, Y., Kovalchuk, I., & Kovalchuk, O. (2020). In search of preventive strategies: Novel high-CBD Cannabis sativa extracts modulera ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY), 12(22), 22425–22444. https://doi.org/10.18632/aging.202225

41. Webb, M. B., Sickles, S., Weaver, C., & Osborn, J. (2020). Increased Pulmonary Function Following ledning of a CBD-Containing Compound NCMB-1 in Fibrotic Lungs of African Green Monkeys. The FASEB Journal, 34(S1), 1–1. https://doi.org/10.1096/fasebj.2020.34.s1.05699

42. Zurier, R. B., & Burstein, S. H. (2016). Cannabinoids, inflammation, and fibrosis. FASEB Journal: tjänsteman Publication of the statsförbund of American Societies for Experimental Biology, 30(11), 3682–3689. https://doi.org/10.1096/fj.201600646R